Medtronic plc (MDT) Total Return CAGR:-5.87%(TTM)
The total return cagr for Medtronic plc (MDT) is -5.87% over the latest trailing 12-month period. The comparable SPY value is +22.12%. Year-to-date total return is -15.77%. Total return includes price appreciation and reinvested dividends.
The total return CAGR for Medtronic plc (MDT) stock is -5.87% over the past 12 months. The 3 year CAGR is 1.85% and the 5 year CAGR is -5.60%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Medtronic plc's investment performance.
MDT Total Return CAGR Chart
Medtronic plc (MDT)
MDT Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
MDT Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 1115.48 | 939.54 | -175.94 | -15.77% | -15.77% |
| 2025 | 899.27 | 1115.48 | +216.21 | +24.04% | +24.04% |
| 2024 | 896.83 | 899.27 | +2.44 | +0.27% | +0.27% |
| 2023 | 818.22 | 896.83 | +78.61 | +9.61% | +9.61% |
| 2022 | 1056.41 | 818.22 | -238.19 | -22.55% | -22.55% |
| 2021 | 1171.38 | 1056.41 | -114.97 | -9.81% | -9.81% |
| 2020 | 1108.54 | 1171.38 | +62.84 | +5.67% | +5.67% |
| 2019 | 870.58 | 1108.54 | +237.97 | +27.33% | +27.33% |
| 2018 | 755.78 | 870.58 | +114.79 | +15.19% | +15.19% |
| 2017 | 652.18 | 755.78 | +103.61 | +15.89% | +15.89% |
| 2016 | 689.70 | 652.18 | -37.53 | -5.44% | -5.44% |
| 2015 | 634.97 | 689.70 | +54.74 | +8.62% | +8.62% |
| 2014 | 495.56 | 634.97 | +139.41 | +28.13% | +28.13% |
| 2013 | 346.85 | 495.56 | +148.71 | +42.87% | +42.87% |
| 2012 | 313.48 | 346.85 | +33.37 | +10.64% | +10.64% |
| 2011 | 296.27 | 313.48 | +17.21 | +5.81% | +5.81% |
| 2010 | 343.73 | 296.27 | -47.46 | -13.81% | -13.81% |
| 2009 | 241.16 | 343.73 | +102.57 | +42.53% | +42.53% |
| 2008 | 378.74 | 241.16 | -137.58 | -36.33% | -36.33% |
| 2007 | 399.59 | 378.74 | -20.85 | -5.22% | -5.22% |
| 2006 | 426.42 | 399.59 | -26.84 | -6.29% | -6.29% |
| 2005 | 365.34 | 426.42 | +61.08 | +16.72% | +16.72% |
| 2004 | 355.82 | 365.34 | +9.53 | +2.68% | +2.68% |
| 2003 | 331.83 | 355.82 | +23.99 | +7.23% | +7.23% |
| 2002 | 370.12 | 331.83 | -38.29 | -10.35% | -10.35% |
| 2001 | 434.40 | 370.12 | -64.28 | -14.80% | -14.80% |
| 2000 | 261.16 | 434.40 | +173.23 | +66.33% | +66.33% |
| 1999 | 265.12 | 261.16 | -3.96 | -1.49% | -1.49% |
| 1998 | 186.57 | 265.12 | +78.56 | +42.11% | +42.11% |
| 1997 | 120.19 | 186.57 | +66.38 | +55.23% | +55.23% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 940 | -7.7% | -4.1% |
| Q1 2026 | 1,018 | -9.6% | -0.2% |
| Q4 2025 | 1,126 | +4.0% | +23.8% |
| Q3 2025 | 1,083 | +10.5% | +8.9% |
| Q2 2025 | 980 | -3.9% | +10.1% |
| Q1 2025 | 1,020 | +12.0% | +11.4% |
| Q4 2024 | 910 | -8.4% | +1.5% |
| Q3 2024 | 994 | +11.7% | +17.0% |
| Q2 2024 | 890 | -2.8% | -3.8% |
| Q1 2024 | 916 | +2.1% | +8.2% |
| Q4 2023 | 897 | +5.6% | +10.4% |
| Q3 2023 | 850 | -8.1% | -4.3% |
| Q2 2023 | 924 | +9.3% | +1.4% |
| Q1 2023 | 846 | +4.1% | -26.2% |
| Q4 2022 | 812 | -8.5% | -23.9% |
| Q3 2022 | 887 | -2.6% | -32.1% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha